Welcome to the AD/PD™ 2022 Interactive Program
The conference will officially run on Central European Time (CET) - Barcelona Time
To convert the conference times to your local time Click Here
Session Description:
This symposium will introduce the need for new treatments for Alzheimer’s disease and Parkinson’s disease that go beyond symptomatic control and potentially treat the underlying causes of each disease. During this session, the pathophysiology of Alzheimer’s disease will be examined and drug targets other than amyloid and tau considered, including key data published on these targets to date. There will also be a presentation on neuroinflammation as an aspect of neurodegenerative diseases and a potential target for the treatment of both Alzheimer’s disease and Parkinson’s disease. Finally current treatments for Parkinson’s disease will be discussed briefly, as well as treatments currently being investigated in clinical trials, to provide a perspective on how the treatment landscape may change from symptomatic control to treatment in the future. These topics will be discussed by the expert faculty, who will also address any questions from attendees.
Session Description:
We invite you to join our eminent faculty in this Biogen symposium where we will discuss new perspectives on Alzheimer’s disease pathophysiology, explore what matters to people living with Alzheimer’s disease, and have a case-based discussion where we seek to translate our evolving understanding into clinical care. We look forward to welcoming you to what promises to be an insightful symposium.
Session Description:
During the symposium Dr Lleo and Dr Palmqvist will discuss the currently available Alzheimer’s Disease diagnostic biomarkers and their usefulness in clinical practice. They will look to the future and share the latest data on possible new Alzheimer’s Disease diagnostic biomarkers and their potential use in clinical practice. After sharing the data, the speakers will present clinical cases to highlight the clinical implications of Alzheimer’s Disease diagnostic biomarkers now & in the future. There will be time allocated for a question-and-answer session to explore further the area of diagnostic biomarkers as an enabler of Alzheimer’s disease treatment